GRCE 8-K Furnishes Quarterly Results via Exhibit 99.1

Rhea-AI Filing Summary

Grace Therapeutics, Inc. furnished a press release announcing its financial results for the three months ended June 30, 2025. The press release is attached to this report as Exhibit 99.1, and an Inline XBRL cover page is provided as Exhibit 104. The company states that the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, which limits the filing liabilities for this disclosure.

The Form 8-K identifies the issuer as Grace Therapeutics GRCE on The Nasdaq Stock Market) and is signed by Chief Executive Officer Prashant Kohli. The Form itself does not include the detailed financial line items in-line; those figures are conveyed in the attached press release exhibit.

Insights

Securities Analyst

TL;DR: Routine 8-K furnishing of quarterly results; information is furnished, not filed, so the disclosure is standard and of limited standalone impact.

The Form 8-K reports that Grace Therapeutics furnished a press release with financial results for the three months ended June 30, 2025, attached as Exhibit 99.1, with an Inline XBRL cover page as Exhibit 104. Because the company explicitly states the exhibit is "furnished, not filed," the legal exposure under Section 18 is limited. The 8-K itself contains no financial line items in the body, so investors must review Exhibit 99.1 for the substantive numbers. This disclosure is a routine earnings-period filing and, absent material surprises in the press release, is unlikely to be market-moving by itself.

Corporate Governance Expert

TL;DR: Governance-compliant disclosure; signature by the CEO and exhibit labeling are standard and pose no immediate governance concerns.

The filing follows typical governance and SEC disclosure practice by furnishing the earnings press release as an exhibit and including an Inline XBRL cover page. The CEO, Prashant Kohli, signed the report, which indicates executive-level attestation of the submission. The explicit language that the exhibit is "furnished, not filed" is standard and indicates the company is not incorporating the press release into prior filings. There are no governance red flags evident from the 8-K text provided.

false0001444192DE00014441922025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

GRACE THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

State of Delaware	001-35776	98-1359336
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

103 Carnegie Center Suite 300
Princeton, New Jersey		08540
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 609-322-1602

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		GRCE		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition."

On August 12, 2025, Grace Therapeutics, Inc. issued a press release announcing its financial results for the three months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing or document.

Item 9.01 Exhibits.

(d) Exhibits

Exhibit		Description
99.1		Press Release, dated August 12, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			GRACE THERAPEUTICS, INC.
Date:	August 12, 2025	By:	/s/ Prashant Kohli
			Prashant Kohli
			Chief Executive Officer

FAQ

What did Grace Therapeutics (GRCE) disclose in this Form 8-K?

The company furnished a press release announcing its financial results for the three months ended June 30, 2025, attached as Exhibit 99.1, and provided an Inline XBRL cover page as Exhibit 104.

Does the Form 8-K state whether the press release is "filed" or "furnished"?

Yes. The Form 8-K states the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.

Which reporting period do the results cover in the disclosed press release?

The press release announces financial results for the three months ended June 30, 2025.

Where is Grace Therapeutics (GRCE) traded?

Grace Therapeutics' common stock trades on The Nasdaq Stock Market under the ticker GRCE.

Who signed the Form 8-K on behalf of Grace Therapeutics?

The Form 8-K is signed by Prashant Kohli, Chief Executive Officer.